South Korea Endoscopy Devices Market

South Korea Endoscopy Devices Market Analysis

The South Korean endoscopy devices market size is USD 1.18 billion in 2025 and is forecast to register USD 1.64 billion by 2030, expanding at a 6.73% CAGR. This momentum is fueled by the country’s rapidly ageing population, a high burden of gastrointestinal malignancies and the swift uptake of artificial-intelligence-enabled platforms that deliver ≥95% lesion-detection sensitivity and specificity. Rising procedure volumes under the National Cancer Screening Program, widening reimbursement for complex therapies such as endoscopic submucosal dissection and the growth of ambulatory surgery centres (ASCs) are reinforcing demand. Parallel government policies—including the Digital Medical Products Act (January 2025) and the 1st Master Plan for Fostering and Supporting the Medical Device Industry—are catalysing domestic production and export capacity, while AI-driven decision support systems shorten procedure time and raise diagnostic precision. Counterbalancing forces include high upfront equipment costs, complex reprocessing rules and a shortage of skilled endoscopists outside metropolitan hubs, all of which temper adoption in smaller hospitals and clinics.

South Korea Endoscopy Devices Market Trends and Insights

Growing burden of gastrointestinal & oncological disorders

South Korea documented 292,221 new cancer cases in 2024, and the gastric-cancer incidence rate of 27.0 per 100,000 ranked third worldwide. While mortality is falling 4.53% annually, the absolute patient pool rises as the median age climbs beyond 45 years. Biennial esophagogastroduodenoscopy under the National Cancer Screening Program has boosted early-stage detection, lifting 5-year survival to >70% among screened cohorts. Together these epidemiological patterns underpin sustained procedure growth, directly supporting the South Korean endoscopy devices market.

Expansion of National Health Insurance coverage for advanced procedures

Universal health coverage now reimburses high-complexity techniques such as endoscopic submucosal dissection (ESD) for early gastric cancer. National registries show a year-on-year increase in ESD since 2018, particularly among patients ≥60 years. Improved affordability propels device demand but reimbursement gaps remain; micro-costing studies reveal National Health Insurance covers only 71.7% of cystoscopy costs at large hospitals, urging policy fine-tuning^{[1]Uiemo Je & Byeong-Ju Kwon, “A Multicenter Micro-Costing Analysis of Flexible Cystoscopic Procedures in Korea,” icurology.org}.

Government initiatives to strengthen domestic manufacturing

The 1st Master Plan (2023-2027) targets top-five global export status for medical devices, with endoscopy identified as a priority. Complementary acts such as the Digital Medical Products Act set streamlined regulatory pathways for AI-enhanced systems effective 2025. These frameworks attract foreign direct investment while accelerating indigenous R&D, reshaping the competitive field and stimulating the South Korean endoscopy devices market^{[2]Korea Institute for Industrial Economics & Trade, “Korea's Healthcare Industry Set to Take a Big Leap Forward,” investkorea.org}.

Rising adoption of ambulatory/day-case surgery models

Seoul, Busan and Daegu report the highest penetration of ASCs, where procedure costs are 60% lower than in hospital outpatient departments and patient turnover is faster. Upper-GI endoscopies dominate ASC caseloads, driving demand for compact, reusable towers and single-use accessory kits suited to high-throughput environments^{[3]Fred E. Shapiro et al., “Cost Comparison Between ASCs and Hospital Outpatient Departments,” ekja.org}. As payers increasingly favour site-neutral payments, the shift to ASCs should continue through 2027.

High capital & lifecycle maintenance costs

A multicentre 2024 micro-costing study placed average cystoscopy costs at USD 100.8 in one flagship Seoul hospital and USD 119.2 at a public facility; reimbursement covered only 71.7% and 60.6% respectively, leaving significant unfunded gaps. Maintenance and reprocessing account for nearly half of lifecycle expenses, discouraging smaller clinics from purchasing premium systems and constraining the South Korean endoscopy devices market in resource-limited settings.

Risk of device-related infections and complex reprocessing requirements

Endoscope-associated infections, although infrequent, persist because channel designs harbour biofilms. A 2024 nationwide survey recorded 98.9% adherence to reprocessing guidelines yet only 56% compliance in transporting contaminated scopes in sealed containers. Growing attention to infection control is fuelling debate on single-use solutions, but each procedure generates 1.34 kg of waste, raising environmental and cost concerns.

Segment Analysis

By Device Type: Endoscopes Maintain Primacy as Capsules Accelerate

The endoscopes segment delivered 45% of the South Korean endoscopy devices market share in 2024, anchored by high-volume gastric-cancer screening and the rapid infusion of AI algorithms into conventional video scopes. Visualization systems upgraded to 4K/8K bolster diagnostic confidence in tertiary centres, while operative devices grow steadily on rising therapeutic procedures such as ESD.

Capsule systems are poised for a 14% CAGR through 2030, reflecting patient preference for non-invasive technologies and robust connectivity that streams images in real time. Early pilot data show technical completion rates >90% in small-bowel imaging, prompting payer discussions on broader reimbursement. Robotic-assisted platforms, though nascent, achieved an 86.1% technical success rate in colorectal ESD trials and hold promise for complex resections.

By Application: Gastroenterology Dominates Amid Broadening Clinical Footprint

Gastroenterology accounted for 55% of the South Korean endoscopy devices market size in 2024 and remains essential to the biennial National Cancer Screening Program that has 50% participation. Procedure volumes have rebounded to pre-pandemic levels for colonoscopy yet lag for gastroscopy among low-income cohorts, underscoring access challenges that still stimulate equipment demand in public facilities.

Gynaecology is the fastest grower at an 11% CAGR to 2030, propelled by outpatient hysteroscopy and laparoscopic interventions that minimise recovery time. Pulmonology, neurology/ENT and orthopaedics also expand as single-use bronchoscopes, neuroendoscopes and arthroscopes lower cross-infection risk and facilitate same-day discharge.

By End-User: Tertiary Hospitals Lead While ASCs Surge

Tertiary and university hospitals held 78% of revenue in 2024, relying on scale and specialist teams to support investment in AI-ready towers and robotic modules. Their dominance concentrates expertise in metropolitan areas, obliging rural patients to travel for advanced care—a dynamic that underscores the strategic significance of tele-endoscopy platforms.

ASCs, however, are forecast to log a 12% CAGR to 2030, energised by payer preference for cost-efficient sites and patient demand for speedier service. Gastroenterology is the anchor specialty in these facilities, where high turnover favours compact, easy-to-sterilise platforms, further broadening the South Korean endoscopy devices market.

Geography Analysis

Metropolitan zones, notably Seoul, Busan and Daegu, conduct the majority of procedures and house most AI-equipped systems, sustaining technological diffusion. Rural provinces lag because only 35% of endoscopists practice outside large cities, amplifying care inequity and lengthening waitlists. The South Korean government’s fee-for-service regime drives higher volumes in urban centres, reinforcing regional imbalances.

Pandemic-era data showed a sharper colonoscopy decline among low-income groups; recovery has remained incomplete for gastroscopy in the medical-aid population, underlining socioeconomic determinants of utilisation researchgate.net. Insurance expansion for advanced techniques is expected to narrow gaps, yet capital-budget constraints still limit adoption of cutting-edge systems outside tertiary hubs.

Continued investment in ASCs—especially in satellite cities—should disperse capacity more evenly. Coupled with mobile endoscopy vans and remote mentoring platforms, these initiatives could redistribute procedure volumes, gradually levelling the geographic spread of the South Korean endoscopy devices market.

Competitive Landscape

Olympus, Fujifilm and HOYA (PENTAX Medical) anchor the market through extensive service networks and continuous product upgrades. Olympus is piloting an “Intelligent Endoscopy Ecosystem” that integrates AI-based detection and automated reporting for release by March 2026. Fujifilm’s ELUXEO 4K offers multi-light imaging and has gained rapid traction in Seoul’s tertiary centres.

Domestic innovators are gaining ground. ENDOROBOTICS developed the ROBOPERA platform, enhancing ESD efficiency and expanding indications for early gastric lesions. Next Biomedical’s NexPowder aims to become the first Korea-registered standard haemostatic agent, addressing post-procedural bleeding gaps. Lunit’s INSIGHT platform adds AI polyp-detection overlays compatible with existing towers, offering a cost-effective upgrade path for smaller hospitals.

Strategic collaborations accelerate innovation: Medtronic’s 2025 distribution agreement with Dragonfly Endoscopy widens access to advanced pancreaticobiliary tools in East Asia. International OEMs often partner local firms for after-sales support, navigating Korea’s rigorous but transparent regulatory environment.